170 related articles for article (PubMed ID: 12692785)
21. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
[TBL] [Abstract][Full Text] [Related]
22. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
[TBL] [Abstract][Full Text] [Related]
23. Sex steroids and bone turnover markers in men with symptomatic vertebral fractures.
Tuck SP; Scane AC; Fraser WD; Diver MJ; Eastell R; Francis RM
Bone; 2008 Dec; 43(6):999-1005. PubMed ID: 18817902
[TBL] [Abstract][Full Text] [Related]
24. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
[TBL] [Abstract][Full Text] [Related]
25. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
26. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
27. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
28. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Suzuki K; Takahashi K
J Urol; 2006 Oct; 176(4 Pt 1):1387-91. PubMed ID: 16952639
[TBL] [Abstract][Full Text] [Related]
29. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia.
Nakamura T; Scorilas A; Stephan C; Jung K; Soosaipillai AR; Diamandis EP
Cancer Res; 2003 Oct; 63(19):6543-6. PubMed ID: 14559849
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: a re-evaluation.
Michael A; Stephan C; Kristiansen G; Burckhardt M; Loening SA; Schnorr D; Jung K
Prostate; 2005 Jan; 62(1):34-9. PubMed ID: 15389818
[TBL] [Abstract][Full Text] [Related]
31. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
32. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
33. Circulating steroid hormones and the risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley W; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):86-91. PubMed ID: 16434592
[TBL] [Abstract][Full Text] [Related]
34. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
Lee SE; Chung JS; Han BK; Park CS; Moon KH; Byun SS; Choe G; Hong SK
Eur Urol; 2008 Dec; 54(6):1324-32. PubMed ID: 18339472
[TBL] [Abstract][Full Text] [Related]
35. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
36. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
37. Tissue polypeptide specific antigen serum concentrations in patients with newly diagnosed prostatic diseases.
Wolff JM; Rohde D; Borchers H; Jakse G
Anticancer Res; 2000; 20(6D):5003-5. PubMed ID: 11326658
[TBL] [Abstract][Full Text] [Related]
38. The effects of short-term oral phytoestrogen supplementation on the hypothalamic-pituitary-testicular axis in prostate cancer patients.
Rannikko A; Petas A; Raivio T; Jänne OA; Rannikko S; Adlercreutz H
Prostate; 2006 Jul; 66(10):1086-91. PubMed ID: 16637075
[TBL] [Abstract][Full Text] [Related]
39. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
40. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study.
Mohr BA; Guay AT; O'Donnell AB; McKinlay JB
Clin Endocrinol (Oxf); 2005 Jan; 62(1):64-73. PubMed ID: 15638872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
